Payment overview · 2025
General Payments
$678.26
28 reported records · 10 companies
Healthcare provider profile · identity verified
Walter P. Griffey, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PARIS, TN · NPI 1295708469
Verified facts
What the public records show
CMS Open Payments records show Walter P. Griffey, M.D. received $678.26 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 53.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $359.46 | 53.0% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $83.60 | 12.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.49 | 6.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.69 | 6.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.90 | 6.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $31.43 | 4.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.81 | 3.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.73 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.36 | 2.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.79 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $678.26 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $294.23 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $83.60 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.76 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.49 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.69 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $31.43 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 217 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
217 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 752 | 170 |
| Losartan Potassium | Losartan Potassium | 556 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 489 | 110 |
| Gabapentin | Gabapentin | 484 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 456 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 404 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 384 | 83 |
| Alprazolam | Alprazolam | 351 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 302 | 57 |
| Omeprazole | Omeprazole | 292 | 67 |
| Lisinopril | Lisinopril | 260 | 68 |
| Trazodone Hcl | Trazodone Hcl | 235 | 55 |
| Furosemide | Furosemide | 224 | 44 |
| Eliquis | Apixaban | 217 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 33 |
| Simvastatin | Simvastatin | 205 | 54 |
| Metformin Hcl | Metformin Hcl | 173 | 44 |
| Potassium Chloride | Potassium Chloride | 164 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 161 | 25 |
| Sertraline Hcl | Sertraline Hcl | 160 | 40 |
| Glimepiride | Glimepiride | 157 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 33 |
| Meloxicam | Meloxicam | 144 | 37 |
| Azithromycin | Azithromycin | 134 | 96 |
| Carvedilol | Carvedilol | 129 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 32 |
| Cephalexin | Cephalexin | 102 | 64 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 100 | 21 |
| Allopurinol | Allopurinol | 99 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 98 | 28 |
| Prednisone | Prednisone | 97 | 55 |
| Famotidine | Famotidine | 94 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 24 |
| Jardiance | Empagliflozin | 92 | 14 |
| Bupropion Xl | Bupropion Hcl | 87 | 21 |
| Montelukast Sodium | Montelukast Sodium | 87 | 22 |
| Mirtazapine | Mirtazapine | 81 | suppressed |
| Clonazepam | Clonazepam | 80 | suppressed |
| Temazepam | Temazepam | 76 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 21 |
| Lorazepam | Lorazepam | 70 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 70 | 50 |
| Tramadol Hcl | Tramadol Hcl | 67 | 21 |
| Donepezil Hcl | Donepezil Hcl | 64 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 38 |
| Atenolol | Atenolol | 61 | 15 |
| Fenofibrate | Fenofibrate | 61 | 13 |
| Ozempic | Semaglutide | 61 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 18 |
| Ezetimibe | Ezetimibe | 60 | 19 |
| Lovastatin | Lovastatin | 60 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | suppressed |
| Pregabalin | Pregabalin | 55 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 21 |
| Baclofen | Baclofen | 52 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 52 | 11 |
| Metformin Hcl Er | Metformin Hcl | 52 | 15 |
| Warfarin Sodium | Warfarin Sodium | 52 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 50 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 18 |
| Meclizine Hcl | Meclizine Hcl | 42 | 11 |
| Nitroglycerin | Nitroglycerin | 42 | 26 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 27 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 25 |
| Torsemide | Torsemide | 39 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Dutasteride | Dutasteride | 38 | 11 |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Ramipril | Ramipril | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 20 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 32 | 32 |
| Cefdinir | Cefdinir | 32 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 13 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Metronidazole | Metronidazole | 31 | 18 |
| Sucralfate | Sucralfate | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 18 |
| Fluconazole | Fluconazole | 30 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 19 |
| Amoxicillin | Amoxicillin | 24 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $678.26 · 28 records | Novo Nordisk Inc | ELIQUIS, FARXIGA, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error